[Management in Senegal of the 1st efficacy and tolerability studies of ivermectin (MK 933) in human onchocerciasis].
In 1981, 32 adult Senegalese males infected with Onchocerca volvulus but without ocular involvement were treated by groups of 8 with single oral dosages of 5, 10, 30 or 50 micrograms/kg of ivermectin . As soon as the second day after treatment, we observed a marked decrease of the dermal microfilaremic charge after a posology of 30 micrograms/kg. However the decrease is most important in the group subjected to 50 micrograms/kg and 75% of them had no more microfilariae in the dermis 28 days following treatment.
D000818:Animals; D000871:Anthelmintics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic / Q000379:methods; D005369:Filaricides / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006801:Humans; D007559:Ivermectin; D007783:Lactones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D007928:Lethal Dose 50; D008297:Male; D009855:Onchocerciasis / Q000188:drug therapy*; D012675:Senegal
D000871:Anthelmintics; D005369:Filaricides; D007783:Lactones; D007559:Ivermectin
Conduite au Sénégal des premières études d'efficacité et de tolérance de l'ivermectine (MK 933) dans l'onchocercose humaine.